Learn More-External Link
Trending at Lumira Ventures
Archemix Files for IPO
Learn More-External Link
Pharmasset and Roche Initiate Studies to Advance R7128 for HCV
Learn More-External Link
Nasrat Hakim Joins Alexza Pharmaceuticals as Vice President, Quality
Learn More-External Link
Depomed Announces Results of Phase 3 Clinical Trial for Gabapentin GR(TM) In Postherpetic Neuralgia
Learn More-External Link
U-Systems, Inc. Raises $16.5M in Additional Venture Funding
Learn More-External Link
Morphotek CEO Named Ernst & Young Entrepreneur Of The Year® 2007 Award Winner
Learn More-External Link
MAKO Surgical Corp. CEO is named Ernst & Young Entrepreneur Of The Year
FORT LAUDERDALE, Fla. – MAKO Surgical Corp. announced today that its President & CEO Maurice R. Ferré, M.D., has received the Ernst & Young Entrepreneur of the Year 2007 award for emerging companies in Florida. The Ernst & Young Entrepreneur …
Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839
Learn More-External Link
Healthcare Acquisition Corp. and Pharmathene receive stockholder approval for their merger
DES MOINES, IA and ANNAPOLIS, MD, August 3, 2007 – Healthcare Acquisition Corp. (AMEX: HAQ), a publicly-traded special purpose acquisition company, and PharmAthene, Inc., a biodefense company developing and commercializing medical countermeasures againstbiological and chemical threats, today announced that the …
Alexza Pharmaceuticals Expands Staccato(R) Migraine Product Portfolio
Learn More-External Link
Archemix and Merck KGaA Sign Strategic Alliance
Cambridge, MA – June 11, 2007 – Archemix Corp. and Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that they have formed a multi-year strategic alliance to discover, develop and commercialize first-in-class aptamer therapeutics with a primary focus …
Archemix and Takeda to Enter into Collaboration for Discovery and Development …
Cambridge, MA and Osaka, Japan — June 11, 2007 — Archemix Corp. (“Archemix”) and Takeda Pharmaceutical Company Limited (“Takeda “) announced today that both parties have signed a multi-year, three target agreement that focuses on the discovery, development and commercialization of first-in-class aptamer-based therapeutics. Under …
Archemix Announces Completion of Phase 1 Trial of ARC1779
Learn More-External Link
MAKO Surgical Corp. Names Charles W. Federico to Board of Directors
FORT LAUDERDALE, Fla. (June 6, 2007) – MAKO Surgical Corp., a developer of minimally invasive, robotic-enabled techniques for knee surgery, announced today that Charles W. Federico has been named to the company’s Board of Directors, effective June 5. Federico has …